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Abstract
Background: Depression screening in chronic disease is advocated but its impact on routine practice is uncertain.
We examine the effects of a programme of incentivised depression screening in chronic disease within a UK primary
care setting.
Methods and Findings: Cross sectional analysis of anonymised, routinely collected data (2008-9) from family
practices in Scotland serving a population of circa 1.8 million. Primary care registered patients with at least one of
three chronic diseases, coronary heart disease, diabetes and stroke, underwent incentivised depression screening
using the Hospital Anxiety and Depression Score (HADS).
125143 patients were identified with at least one chronic disease. 10670 (8.5%) were under treatment for
depression and exempt from screening. Of remaining, HADS were recorded for 35537 (31.1%) patients. 7080 (19.9%
of screened) had raised HADS (≥8); majority had indications of mild depression with HADS between 8 and 10. Over
6 months, 572 (8%) of those with raised HADS (≥8) were initiated on antidepressants, while 696 (2.4%) patients with
normal HADS (<8) were also initiated on antidepressants (relative risk of antidepressant initiation with raised HADS
3.3 (CI 2.97-3.67), p value <0.0001). Of those with multimorbidity who were screened, 24.3% had raised HADS (≥8).
A raised HADS was more likely in females, socioeconomically deprived, multimorbid or younger (18-44) individuals.
Females and 45-64 years old were more likely to receive antidepressants.
Limitations: retrospective study of routinely collected data.
Conclusions: Despite incentivisation, only a minority of patients underwent depression screening, suggesting that
systematic depression screening in chronic disease can be difficult to achieve in routine practice. Targeting those at
greatest risk such as the multimorbid or using simpler screening methods may be more effective. Raised HADS was
associated with higher number of new antidepressant prescriptions which has significant resource implications. The
clinical benefits of such screening remain uncertain and merits investigation.
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Introduction
Depression is up to two to three times more common in
patients with chronic disease as compared to the general
population [1-3]. Prevalence estimates of depression in
patients with chronic diseases such as coronary heart disease
(CHD), diabetes and previous stroke range from 15-25% [4–6],
depending on screening methods. Depression comorbid with
chronic disease is known to have detrimental effects on
mortality, clinical outcomes, treatment adherence and
functional outcomes such as ability to carry out activities of
daily living [5,7,8]. Routine depression screening for patients
with chronic disease is now being advocated [9,10]. In the UK,
family practices have been incentivised to carry out annual
depression screening in those with chronic disease as part of a
pay for performance contract since 2006 [11]. However, the
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evidence supporting the clinical effectiveness of routine
depression screening in the general population is equivocal
[12], with recent systematic reviews arguing both in favour and
against it [13,14]. There is also evidence to suggest that routine
depression screening in patients with cardiovascular disease
may not lead to improvement in clinical outcomes [15,16].
A range of self-report questionnaires are currently used for
depression screening in primary care; however not all were
designed to be used in patients with chronic disease and the
best method for screening for depression in chronic disease
remains uncertain. A recent meta-analysis concluded that none
of the currently available depression screening questionnaires
were sufficiently accurate to be recommended as a definitive
tool [17]. In the UK, the National Institute for Health and Care
Excellence (NICE) recommends depression screening or case
finding in patients with chronic disease [18], although there is
still some controversy about the benefits of such an approach
[19].
It is noteworthy that most of the evidence regarding the
accuracy and clinical effectiveness of depression screening in
patients with chronic disease has come from randomized
controlled trials with little known about the feasibility or effects
of widespread screening in routine practice.
In this paper we examine the reach and effects of a
programme of incentivised depression screening in chronic
disease within a UK primary care setting. Our specific research
questions are: (1) What is the uptake of screening for
depression in chronic disease in routine primary care(2)? What
is the impact of the screening questionnaire score (in this
study, HADS) on the rate of antidepressants prescribed(3)?
What are the demographic factors influencing a positive result
on depression screening and subsequent initiation of
antidepressants?
Methods
Ethics Statement
We received approval from the West of Scotland research
ethics committee to undertake this work. Permission to analyse
the anonymised data for the year 2008-9 was provided by the
NHS Greater Glasgow and Clyde Enhanced Services data
group, which was the authorised “guardian” of this data set.
The work involved analysis of a large routinely collected
dataset. The data received was completely anonymised and
the research team did not have access to patient identifiers.
In view of this, we did not seek individual patient consent to
undertake this work. This was in agreement with the guidance
given by the local ethics committee and the guardians of the
dataset.
Data Collection
The data reported in this paper came from the West of
Scotland, with a population of circa 1.8 million served by two
different health boards. The local health boards oversee a
programme of incentivised depression screening in chronic
disease as part of a wider chronic disease management
programme of ‘Local Enhanced Services’ (LES). The Quality &
Outcomes Framework (QOF) is part of the UK wide, pay for
performance, General Medical Services contract for family
practitioners [20]. The QOF is an incentive scheme containing
a group of clinical indicators, where primary care practices are
paid based on how well they score for each indicator, which is
dependent on their clinical performance against any given
indicator. LES are contractual arrangements at a local health
board level with family practices designed to augment the basic
QOF specification by incentivising additional indicators that are
deemed to be particularly important by a given area and there
are no penalties for non-adherence. In the areas under
investigation in our study, family practices were paid under the
LES scheme to carry out a comprehensive annual health
assessment for patients with three common chronic diseases,
CHD, diabetes and stroke, including depression screening.
Besides depression screening, the annual health assessment
also included assessment and management of other health
related behaviours such as smoking status, alcohol
consumption, diet and activity levels. The annual health
assessment was usually carried out by a practice nurse and
lasted for one hour. The remuneration offered varied according
to disease area with £31 each for patients with diabetes, £26
each for patients with previous stroke and £23 each for patients
with CHD. The remuneration was dependent on the level of
coverage of indicators achieved in the health assessment, with
full payment offered for >90% coverage, 3/4 payment for
75-90% coverage and half payment for 60-75% coverage.
In 2008-9, the period on which the current study is based,
the comprehensive annual health assessment was offered to
all patients on the practice register with one of the three
aforementioned chronic diseases and was usually carried out
by practice nurses. The annual health assessment protocol
was based on a universal template issued by the health board
and it was specific for each of the three diseases (see
appendix S1). The results of the assessment were entered into
the template with “Read codes” assigned to each data entry.
Read codes are the coded thesaurus of clinical terms, by which
clinicians in the UK record patient findings and procedures [21].
The assessment included detailed history taking, various
physical examinations and blood tests, and recording of certain
drugs prescribed including antidepressants, anti-psychotics
and cardiovascular drugs.
Importantly, the health assessment included screening
patients for depression using the depressive subscale of the
Hospital Anxiety and Depression Score (HADS-D) [22].
Patients, who were noted to be under treatment for depression,
were exempt from depression screening. The template
recommended that patients with HADS of 11 or more should be
considered for cognitive behavioural therapy or
pharmacotherapy, either by the practice nurse doing the
assessment or via subsequent review by the family practitioner,
whichever was deemed appropriate by the practice. Patients
with HADS of 8-10 were to be advised about low intensity
psychosocial interventions such as self-help services or useful
online resources [23,24].
Data Processing and Analysis
The data consisted of Read codes, which identified specific
measures, the value of each measure taken and the date
Depression Screening in Chronic Disease
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recorded. Read code identification was based on a list provided
by the health board (see appendix S1). Read code entries were
converted into clinical values for analysis and independently
validated by a second researcher. The validation process
continued until both researchers were in agreement.
We restricted our analysis to adults aged from 18 to 90 and
health assessments recorded between 01/04/2008 to
31/03/2009. We analyzed the prescription records of those
patients, who did not have depression screening results
recorded, for an antidepressant prescription in the 12 month
observation period. We were not able to explicitly differentiate
which of the patients in this category were newly prescribed
antidepressants. However based on our situational knowledge
of primary care practice in Scotland, that the average
prescription duration is not usually longer than 90 days, we
further classified these patients into those ‘likely’ to be newly
started on antidepressants. If patients in this category were first
prescribed antidepressants more than 90 days after the start of
the observation period, they were labelled as ‘likely’ to be
newly started on antidepressants without undergoing
depression screening. Patients were labelled as ‘under
treatment’ for depression and exempt from depression
screening if: (a) they were noted to be on antidepressants
based on their prescription record with no record of depression
screening during the 12 month observation period (01/04/2008
to 31/03/2009) (b) the first prescription for antidepressant was
issued in the first 3 months of observation period. The full list of
antidepressants prescribed can be accessed from appendix
S2.
The depressive subscale of HADS (HADS-D), which gives a
total score of 21, was used as a screening tool. A score of ≥11
is considered a clinically significant disorder, whereas a score
between 8 and 10 suggests a mild disorder [22]. We used the
threshold of HADS ≥8 as a cut-off for a ‘positive screening
result’ as there is evidence to suggest that this offers an
optimal balance of sensitivity and specificity [25-27] and such
an approach has been endorsed by national guidelines [28]. All
patients who underwent depression screening were checked
for a new prescription of antidepressants in the six months after
the date of assessment. No reliable information was available
on the number of patients who were referred for psychological
therapies following their depression screening. We also did not
have information on history of previous episodes of depression
or history of antidepressants prescribed in the past, prior to the
observation period. We considered the effects of screening for
each of the diseases individually and in combination. The
socioeconomic status was provided to us in the form of the
Scottish Index of Multiple Deprivations (SIMD) score, which
identifies small area concentration of multiple deprivations
across all of Scotland in a consistent way. The SIMD score was
divided into quintiles from 1-5 with Q1 representing the most
deprived area [29]. Smoking status was divided into current
non-smokers and smokers; alcohol status was classified into
moderate (< 21 units men, <14 units women), hazardous
(21-50 units men, 14-35 units women) and harmful (>50 units
men, >35 units women) based on their weekly units
consumption. This classification was adapted from the latest
report of the Scottish Health Survey [30]. The other variables
for health related behaviour such as diet and physical activity
levels all had a large number of missing values and hence
were excluded from all analyses.
Statistical Analysis
The incidence of a positive screening was calculated for
single diagnoses and for both 2 and 3 co-morbidities. The
incidence rate was calculated as the number of positive results
found as a result of depression screening (defined as HADS
≥8) of the total number of patients screened in each diagnostic
or demographic subgroup. Similarly, the rate of new
antidepressant treatment was calculated by dividing the
number of subjects with a raised HADS who started treatment,
by the total number with a raised HADS. Logistic regression
models were used to examine whether age, gender,
deprivation quintile and multimorbidity were associated with the
odds of screened patients having a raised HADS; and on the
odds of starting a new antidepressant treatment given a raised
HADS following screening. Results of the regression models
are presented as the odds ratios associated with either a fixed
increase in the value of the predictor (for continuous predictors)
or compared to the stated reference group (for categorical
predictors), with 95% confidence intervals (CI) and p-values.
We visualise the logistic regression analysis by presenting the
corresponding predicted probabilities of new treatment
depending on a patient’s age, gender and HADS, and adjusted
for deprivation and comorbidity, to allow inference for other
patients meeting these criteria.
We present a Kaplan-Meier plot to illustrate the time from
start of monitoring to starting new treatment dependent on
whether patients were screened for depression or not. All
subjects were followed up for 6 months and patients who did
not start treatment were censored at 6 months. Patients in the
screened population were stratified by whether they had a
HADS<8, 8 to 10 or ≥11.
Analysis was carried out using the R statistical software,
version 15.1 [31]
Results
Section 1. Uptake of Depression Screening in Routine
Practice
A total of 125,143 patients were listed as having CHD,
diabetes or stroke in the year 2008-09. Figure 1 shows the
distribution of patients across the three diseases and their
respective proportional combinations.
Figure 2 shows the distribution of patients according to their
depression status. Of the total sample, 10,670 (8.5%) patients
were under treatment for depression, having received their first
antidepressant prescription of the observation period within the
first 3 months and were thus exempt from screening. The
remaining 114,473 (91.5% of total sample size) patients were
eligible for depression screening. However, depression
screening was only undertaken in 35,537 (31.1% of those
eligible) and 78,936 (68.9%) were not screened.
Table 1 provides the details of the demographic
characteristics of those with known depression status and
those with unknown depression status, along with 95%
Depression Screening in Chronic Disease
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confidence intervals (CIs) for the differences between them.
These show that, due to the extremely large sample size, there
were significant differences between the two groups for all
characteristics except smoking (for which there is a high level
of missing data, likely to be biased since most of the data on
non-smokers was missing). However the CIs show that the
magnitude of all of the differences was extremely small,
suggesting that those screened were similar to those not
screened in terms of their demographics.
Section 2. Impact of Depression Screening on
Antidepressant Prescribing
Figure 2 shows that, of the screened patients, 7080 (19.9%)
were identified as screen positives based on HADS ≥8, of
which 572 (8%) (relative risk against those with HADS<8, 3.3
Figure 1.  Distribution of patients across three diseases for the year 2008-09.  
doi: 10.1371/journal.pone.0074610.g001
Figure 2.  Flow chart showing the outcome of depression screening.  
doi: 10.1371/journal.pone.0074610.g002
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(CI 2.97-3.67), p value <0.0001) were initiated on new
antidepressant treatment within the observation period. Only
2925 (8.2% of screened) patients had an indication of
moderate to severe depression with HADS ≥11 and of these
303 (10.4%) received a new anti-depressant prescription within
6 months of their assessment. This was the threshold
recommended by the health board for considering
pharmacotherapy. Finally, 696 (2.4%) of 28,457 patients with a
Table 1. Comparison of patients with known depression
status versus those with unknown depression status.
  
Depression
Status
Unknown
(N=73947)
Depression
Status Known
(N=51196)
95% CI for the
difference
between
known and
unknown
Age (years) Mean (SD) 67.1 (14.4) 67.7 (12.3) (0.42, 0.72)
 Median (IQR) 69.0 (58, 78) 69.0 (60, 77  
 missing 30 12  
Age (years) 18-44 5265 (7.1%) 1951 (3.8%) (-3.6%, -3.1%)
 45-64 23225 (31.4%) 17270 (33.7%) (1.8%, 2.9%)
 65-75 19390 (26.2%) 15082 (29.5%) (2.7%, 3.7%)
 76-90 26037 (35.2%) 16881 (33.0%) (-2.8%, -1.7%)
 missing 30 12  
Sex Female 33210 (44.9%) 24356 (47.6%) (2.1%, 3.2%)
 Male 40693 (55.1%) 26814 (52.4%)  
 missing 44 26  
Quintile
(most
deprived =
1)
1  27708(38.5%)
 21065
(42.0%) (3.0%, 4.1%)
 2 14335 (19.9%) 9567 (19.1%) (-1.3%, -0.4%)
 3 11124 (15.5%) 6272 (12.5%) (-3.3%, -2.5%)
 4 9056 (12.6%) 5422 (10.8%) (-2.1%, -1.4%)
 5 9746 (13.5%) 7775 (15.5%) (1.6%, 2.4%)
 missing 1978 1095  
Co-
morbidity
Single
diagnosis 61445 (83.1%) 39774 (77.7%) (-5.9%, -5.0%)
 Twodiagnoses 11355 (15.4%) 10311 (20.1%) (4.3%, 5.2%)
 Threediagnoses 1147 (1.6%) 1111 (2.2%) (0.5%, 0.8%)
 missing 0 0  
Smoking Current non-smoker 14484 (61.3%) 13236 (61.8%) (0.4%, 1.4%)
 Smoker 9144 (38.7%) 8178 (38.2%)  
 missing 50319 29782  
Alcohol
(units/week) Moderate 17689 (95.6%) 37030 (0.7%, 1.4%)
 Hazardous 673 (3.6%) 1138 (3.0%) (-1.0%, -0.3%)
 Harmful 138 (0.8%) 149 (0.4%) (-0.5%, -0.2%)
 missing 55447 12879  
Mean (SD) and median (IQR) are presented for continuous variables and count
(%) for categorical.
doi: 10.1371/journal.pone.0074610.t001
normal HADS (<8) were also started on new antidepressants
during the observation period.
Figure 2 also shows that 4989 patients in the non-screened
population of 78,936 received their first antidepressant
prescription in the last 9 months of observation period; these
patients were ‘likely’ to be newly treated based on the
assumption outlined in the methods section. Thus, the
estimated overall new antidepressant prescription rate for the
non-screened population was 6.3%. The overall new
antidepressant prescription rate for the screened population
was 3.5% (1268 patients out of 35,537). The new
antidepressant prescription rate was higher for the non-
screened population than for the screened population but it
was lower than the rate for those with a raised HADS (≥8),
which was 8%.
Figure 3 presents the time to starting new treatments for the
screened and non-screened populations. This illustrates the
association between a raised HADS (≥8) recorded at screening
and a greater proportion of patients receiving treatment more
quickly. It is also notable that subjects identified with normal
range HADS (<8) receive the lowest rate of new treatments;
even lower than the overall rate of the non-screened
population.
As a sensitivity analysis, we undertook the analyses with and
without amitriptyline, since it is often used for other indications,
such as diabetic neuropathy. While there were lower
proportions of patients recorded as being on antidepressants
when amitriptyline was excluded, the distribution across the
HADS categories was similar. Appendix S2 reports the full list
of antidepressants prescribed with details of number of patients
for the non-screened and the screened population.
Section 3. Multimorbidity and Depression Screening
Table 2 compares the uptake of depression screening and
the rate of positive depression screening (HADS ≥8) between
patients with one of the three chronic diseases under study,
those with any combination of two diseases and those with all
three chronic diseases. The proportions for uptake and positive
screening result increase along with increasing number of
chronic conditions. Patients with multimorbidity were
significantly more likely to have a positive result on screening
(OR 1.48 (95% CI 1.39-1.58) (Table 3).
Section 4. Patient demographics, depression screening
and antidepressant initiation
Figure 4 illustrates the clear socioeconomic gradient in the
rate of having a positive depression screen (HADS ≥8), with
rates being highest amongst those who were most deprived.
Logistic regression results shown in Table 3 confirm that
patients from the most deprived areas were more than twice as
likely to have a positive result (HADS ≥8) as compared to those
from the least deprived areas (OR 2.56, 95% CI 2.34-2.79).
However, socioeconomic status did not have a significant
impact on probability of starting a new antidepressant among
those with a positive depression screen.
Figure 5 shows that patients from older age groups were less
likely to have a raised HADS (≥8) on depression screening as
compared to their younger counterparts. The youngest and
Depression Screening in Chronic Disease
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oldest patients appeared to have lower rates of initiation of
antidepressants given a raised HADS (≥8) than those in middle
age. Table 3 confirms that the patients aged 45-64 were at
least 1.5 times more likely to be treated with antidepressants
given a raised HADS than the oldest patients (OR 2.00, 95% CI
1.58-2.54).
Table 3 also shows that males were significantly less likely
than females to have a positive result on depression screening
(OR 0.83, 95%CI 0.79-0.89). Amongst positive depression
screens with HADS ≥8, males were also at least 25% less
likely than females to be initiated on antidepressants (OR 0.63,
CI 0.53-0.75).
An increase in HADS was associated with an increase in the
rate of initiation of antidepressants, with each unit increase
above 8 in HADS increasing the odds of treatment by 11% (OR
1.11, CI 1.07-1.14). Figure 6 displays the predicted
probabilities of a subject starting new treatment given a raised
HADS (≥8) against age for each gender and HADS category,
showing how much more likely middle-aged and female
patients were to start treatment than the oldest, youngest and
male patients, for both categories of raised HADS.
Discussion
Summary of Findings and Comparison with Existing
Literature
Despite the fact that primary care practitioners were being
incentivized to screen for depression in chronic disease, a
majority of patients (68.9%) were not documented as having
been screened during the observation period. Depression
screening was low in our study. While inaccuracies in recording
Figure 3.  Antidepressant initiation time for the screened and non-screened population.  
doi: 10.1371/journal.pone.0074610.g003
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the results on the health assessment template could account
for some of the missing results for depression screening in the
database, it seems unlikely that this could provide a full
explanation of our findings. Potential explanations include lack
of family practitioner confidence in the value of HADS-D, it has
lower overall accuracy when compared to other depression
screening tools [17]; or lack of family practitioner support for
this type of screening due to lack of evidence that systematic
depression screening leads to improvement in clinical
outcomes [15,16,32]. Alternatively, previously reported barriers
to discussing depression (or mental health) in patients with
chronic disease in primary care, such as stigma associated
around the ‘label’ and physicians’ preconception of normalizing
depression in patients with chronic disease, could be
influencing factors [33,34].
The rate of positive screens identified as a result of
depression screening in our study of routine practice ranged
from 17-21% for those with a single condition to 26% for those
with multimorbidity. This is consistent with rates of 6-22%
which have been reported in clinical trials of depression
screening [15]. However, epidemiological studies have
reported varying results. In a study of routine primary care
involving more than 10,000 patients in the United States, a
yield of 20.1% positive screens was reported using the PHQ-2
score [35]; while a similar study of 532 patients in Norfolk
reported a much smaller yield of 2.3% using the two stem
questions (‘During the last month, have you often been
bothered by feeling down, depressed or hopeless?’ and ‘During
the last month, have you often been bothered by having little
interest or pleasure in doing things?’) as a screening tool [36].
Interestingly, Burton et al reported a much lower rate of 3% of
new depression cases found from depression screening using
the validated two stem questions [37], based on their analysis
of a large population study from a different database [38].
However, it is difficult to make a direct comparison of our
results with those of Burton et al as their caseness criteria for
depression relied on diagnostic coding entered by health
professionals, which in turn depends on how health
professionals interpret and manage a positive result on
Table 2. Depression screening uptake and proportion of
positive depression screening found across diagnostic
subgroups.
 Single Diagnosis Multiple Diagnoses
 
Stroke
(N=14447)
Diabetes
(N=44247)
CHD
(N=42525)
Two
Diseases*
(N=21666)
All
Diseases
(N=2258)
Eligible for
Screening 12485 37601 38715 18765 1918
Subjects
Screened
3558
(28%)
12082
(32%)
11716
(30%) 7410 (39%) 771 (40%)
Positive
Screening
(HADS ≥8)
753 (21%) 2071(17%)
2271
(19%) 1781 (24%) 204 (26%)
* Subject has two diagnoses of stroke, CHD or diabetes.
doi: 10.1371/journal.pone.0074610.t002
depression screening and data on the rate of positive screens
is unavailable for that study. HADS-D has a specificity of 81%,
when used for depression screening in patients with chronic
physical health problems in a primary care setting [17]. It is
likely that some of the ‘positive screens’ identified in our study
include false positive cases and hence we over-estimate the
yield identified from depression screening. On the other hand,
there is evidence to suggest that family practitioners often
avoid using specific diagnostic codes while recording
Table 3. Regression Tables.
Odds Ratio of having raised HADS
(≥8) for patients who underwent
depression screening, adjusted for
listed variables
Odds Ratio of starting new
antidepressants for patients with
raised HADS (≥8), adjusted for listed
variables
 
Odds
Ratio
(95% CI) p-value  
Odds Ratio
(95% CI) p-value
   HADS (perunit increase)
1.11 (1.07,
1.14) <0.001
Age (vs. 76 to
90)   
Age (vs. 76 to
90)   
65 to 75
1.10
(1.02,
1.17)
0.010 65 to 75 1.56 (1.21,2.02) 0.001
45 to 64
1.81
(1.69,
1.94)
˂0.001 45 to 64 2.00(1.58,2.54) ˂0.001
18 to 44
1.76
(1.52,
2.05)
<0.001 18 to 44 1.58(0.97,2.57) 0.068
Male (vs
Female)
0.83
(0.79,
0.89)
<0.001 Male (vsFemale)
0.63 (0.53,
0.75) <0.001
Comorbidity
(vs single
disease)
1.48
(1.39,
1.58)
<0.001
Comorbidity
(vs single
disease)
1.14 (0.94,
1.39) 0.200
Deprivation
Quintiles (vs.
Q5-least
deprived)
     
Q4
1.27
(1.13,
1.43)
<0.001 Q4 0.88 (0.58,1.33) 0.541
Q3
1.51
(1.35,
1.69
<0.001 Q3 0.88 (0.59,1.29) 0.507
Q2
1.90
(1.72,
2.11)
<0.001 Q2 0.74 (0.52,1.05) 0.094
Q1 - most
deprived
2.56
(2.34,
2.79)
<0.001 Q1 - mostdeprived
0.88 (0.65,
1.19) 0.402
doi: 10.1371/journal.pone.0074610.t003
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depression, which underestimates the actual occurrence in
clinical practice [39,40].
There is growing evidence internationally, that multimorbidity
is the norm rather than the exception, particularly in ageing
populations [41-43]. Our study shows a clear relationship
between the number of chronic diseases and number of
positive screens found on depression screening. Similar
associations between multimorbidity and depression screening
have been reported from a study based on results from a self
reported postal survey in Australian primary care [44]. This
further strengthens the argument put forward by policy makers
and researchers, both in the UK and US, for the need to
consider physical and mental health needs together [45-47].
Importantly, we have shown that higher HADS on depression
screening was associated with higher rates of new
antidepressant prescriptions in routine primary care practice.
This is contrary to previous evidence which has suggested that
depression screening does not lead to increases in
antidepressant prescribing [13,32]. However, our study reports
what happens in routine clinical practice, whereas the existing
evidence draws on findings from randomized controlled trials
with small sample sizes and studies that usually did not focus
on screening for depression comorbid with chronic disease.
The majority of those prescribed antidepressants within six
months of depression screening had either a negative
screening result (HADS <8) or a positive screening with a
probability of mild depression (HADS 8-10). There is little
evidence of additional benefit of antidepressants compared
with placebo in this group of patients [28] and hence this
finding has important clinical and resource implications.
However, this should be considered in the context of recent
evidence of rising antidepressant prescribing in Scotland and
Figure 4.  Title-Depression Screening and Socioeconomic deprivation.  Rate of positive depression screening found from total
screened (upper plot); and rate of anti-depressant initiation from those with raised HADS ≥8 (lower plot), versus socioeconomic
deprivation status.
doi: 10.1371/journal.pone.0074610.g004
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the UK, and the uncertainty whether this rise should be
attributed to increase in case-identification of depression or
increase in duration of depression treatment or both [48-50].
The new antidepressant prescribing rate in the non-screened
population was lower than those with raised HADS but higher
than those with a normal HADS.
Various studies have shown that females and patients who
are from socioeconomically deprived backgrounds are more
likely to develop depression [51,52] but this study is one of the
first to study their impact on results of depression screening in
chronic disease. Our study showed that among the new
depression cases, there was no difference in the rate of
antidepressant initiation amongst different socioeconomic
groups. However, we did find that males were less likely to be
prescribed antidepressants, to the extent that a man with
HADS ≥11 had a similar chance of being prescribed
antidepressants as a woman with HADS of 8-10. This is
contrary to the previous evidence which shows that family
practitioners were more likely to prescribe antidepressants to
male patients presenting with depression [53,54] suggesting
there needs to be further research in this area to study the
impact of gender on depression treatment. We also showed
that middle-aged patients were more likely than the oldest
patients to be initiated on antidepressants, given a raised
HADS. Previous evidence has shown that primary care
professionals often have ‘therapeutic nihilism’ when dealing
with depression in elderly patients [55], which could be one of
the explanations for this observed difference.
Strengths
This is the first study, to our knowledge, to examine the
impact of implementing systematic depression screening for
patients with chronic disease in routine clinical practice. The
study has a large sample size with good representation of
patients from different age groups and socioeconomic
backgrounds. Processing of the large and complex dataset was
Figure 5.  Title- Depression screening and Age.  Rate of positive depression screening found from total screened (upper plot);
and rate of antidepressants initiation from those with raised HADS ≥8 (lower plot) versus age.
doi: 10.1371/journal.pone.0074610.g005
Depression Screening in Chronic Disease
PLOS ONE | www.plosone.org 9 September 2013 | Volume 8 | Issue 9 | e74610
cross validated by two researchers independently for quality
control and robustness. A standardized and validated method
of depression screening was used.
Limitations
This study used routinely collected data that was not initially
intended to be used for research purposes. Since only a
minority of the patients were actually screened, depression
status was unknown for a large number of patients; also
information on health related behaviour was incomplete in the
majority of patients. There may be important differences
between patients with known depression status and those
whose depression status was unknown, which are not evident
from their baseline demographic data. Practitioners may
intuitively screen those patients where they are more likely to
get a positive result, for instance patients with multimorbidity.
Also, there is a possibility of reverse causality with GPs
reviewing a patient whom they consider to have depression
and offering screening subsequently. The overall accuracy of
depression screening in our study was reliant on HADS-D
which may not be the best available screening tool for patients
with chronic disease in a primary care setting [17]. The uptake
for depression screening was much lower in our study when
compared with uptake for depression screening in the QOF
programme in Scotland (90.5%) for the year 2008-09 [56].
However, the QOF programme had target driven incentivisation
where practices were only paid if they achieved 90% coverage
in depression screening. The incentivisation for the LES
programme used in our study instead depended on achieving a
proportion of clinical indicators across the health assessment
protocol. Secondly the screening tool used for the QOF
programme is two stem questions which are much quicker to
administer when compared to the HADS-D questionnaire which
consists of 7 items. Finally we did not have information on the
presence of chronic conditions outside the ones studied, thus
multimorbidity count is likely to be underestimated, nor on the
number of patients referred for psychological therapies
following their depression screening and assessment. We also
did not have information on previous episodes of depression or
previous treatment with antidepressants prior to the
observation period, which are likely to be important influencing
factors on antidepressant initiation rate.
Implications for Practice
Implementation of systematic depression screening for
patients with chronic disease needs careful consideration. Our
study shows that even within the context of incentivisation,
universal coverage can be difficult to achieve in routine
practice, unless simpler screening tools such as two stem
questions are used. Importantly, depression screening
identified large numbers of new cases which has clear
resource implications, especially since it was clear that
Figure 6.  Relationship between probability of new antidepressant treatment, gender, and age and HADS categories,
adjusted for deprivation and comorbidity.  
doi: 10.1371/journal.pone.0074610.g006
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depression screening was associated with increases in anti-
depressant prescribing and antidepressants were prescribed to
patients where there is little evidence of additional benefit
above placebo (HADS<8 and HADS 8-10).
Our data suggests that younger individuals, those with
multimorbidity, and those from more deprived backgrounds
were more at risk of depression in this population, thus
suggesting that targeting depression screening at high risk
groups could be an alternative approach. Males and elderly
patients were less likely to be initiated on antidepressants,
which needs further investigation.
Conclusion
The reach of depression screening in routine practice was
low in our study despite incentivisation. A simpler screening
tool or targeting high risk patient groups may be more feasible
in routine practice, but needs further research. In our study,
identification of depression in chronic disease was associated
with treatment changes in routine practice. The key question
will be to explore how such treatment changes affect
outcomes, if at all.
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